JP2609562B2 - Cream for allergic dermatitis and method for producing the same - Google Patents

Cream for allergic dermatitis and method for producing the same

Info

Publication number
JP2609562B2
JP2609562B2 JP3151176A JP15117691A JP2609562B2 JP 2609562 B2 JP2609562 B2 JP 2609562B2 JP 3151176 A JP3151176 A JP 3151176A JP 15117691 A JP15117691 A JP 15117691A JP 2609562 B2 JP2609562 B2 JP 2609562B2
Authority
JP
Japan
Prior art keywords
extract
cream
action
allergic dermatitis
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP3151176A
Other languages
Japanese (ja)
Other versions
JPH04346917A (en
Inventor
政夫 斎藤
Original Assignee
政夫 斎藤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 政夫 斎藤 filed Critical 政夫 斎藤
Priority to JP3151176A priority Critical patent/JP2609562B2/en
Publication of JPH04346917A publication Critical patent/JPH04346917A/en
Application granted granted Critical
Publication of JP2609562B2 publication Critical patent/JP2609562B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】 本発明はアレルギー性皮膚炎用
クリーム及びその製造法に関し、アレルギー、又特に金
属、化粧品、ウルシ等の接触性皮膚炎に有効なアレルギ
ー性皮膚炎用クリームに関するものである。
The present invention relates to an allergic skin dermatitis <br/> cream and its preparation, allergies, and in particular metal, cosmetics, effective contact dermatitis such as lacquer allergy
Dermatitis cream.

【0002】[0002]

【従来の技術】 抗体が血清に認められず、細胞によっ
て仲介されるアレルギー反応をIV型のアレルギー反応
と呼ぶが、細菌、ウイルスカビ等の感染に伴う反応や、
金属、化粧品、ウルシ等の接触性皮膚炎などがこれに属
する。
2. Description of the Related Art Cell-mediated allergic reactions in which antibodies are not found in serum and are called type IV allergic reactions include reactions associated with infections such as bacteria and viral mold,
Contact dermatitis such as metals, cosmetics, and urushi belong to this category.

【0003】然して細菌等の感染に伴う反応の場合には
細菌等の除去により対応策はあるが、アレルギー、接触
性皮膚炎には適当な対応治療法はステロイドホルモン以
外には提案されていない。
[0003] In the case of a reaction associated with infection by bacteria or the like, there is a countermeasure by removing the bacteria or the like. However, no appropriate treatment other than steroid hormones has been proposed for allergy and contact dermatitis.

【0004】然して甘草根は古くから消炎効果がある薬
草として知られており、その有効成分であるグリチルリ
チン酸類は抗炎、抗アレルギー、抗消化性潰瘍作用など
のため、急性、慢性の皮膚炎の他、アフタ性口内炎など
に効果があるとして基礎化粧品や歯磨中に添加されてい
るものがある。
However, licorice root has long been known as a medicinal herb having an anti-inflammatory effect, and its active ingredient glycyrrhizic acid has an anti-inflammatory, anti-allergic, anti-peptic ulcer effect, etc., so that acute and chronic dermatitis Others have been added to basic cosmetics and dentifrice as being effective for aphthous stomatitis and the like.

【0005】漢方におけるオウゴンの作用は「炎症を去
り、水毒を除き、清涼解熱と離尿の効がある」 (新本
草備要)とされている。オウゴンの一般薬理作用につい
ては緩下作用、離尿作用があることは確認されている。
又、オウゴンの成分がフラボノイドであるところから所
謂ビタミンP様活性として抗炎症作用が調べられ、アス
ピリンに匹敵する効果が認められている。更に、オウゴ
ンの抗アレルギー作用について、感作したモルモットの
摘出回腸でSchultz−Dale反応をみると強い
抑制効果が認められる。
[0005] The effect of Orgon in Chinese medicine is "removed from inflammation, excluding water poisoning, and has the effect of cooling antipyretic and urinating" (Shinmoto herbs). As for the general pharmacological action of gongon, it has been confirmed that it has a laxative action and a urinary action.
In addition, anti-inflammatory activity was examined as a so-called vitamin P-like activity from the fact that the component of pentagon is a flavonoid, and an effect comparable to that of aspirin was recognized. Further, regarding the antiallergic effect of gongo, a strong inhibitory effect is observed when the Schultz-Dale reaction is observed in the isolated ileum of the sensitized guinea pig.

【0006】オウバクは、オウレン、オウゴンと共にベ
ルベリンを主成分とする生薬であるが、漢方に於ける用
法はオウレン、オウゴンと異なる場合が多い。オウバク
については消化器作用、眼疾患など殺菌作用を推測させ
る用法が多い。又、オウバクの薬効には外用剤としての
用法に特徴があり、ベルベリンは外用殺菌剤として単な
る殺菌作用では説明出来ない創面治療促進作用があると
報告されている。
[0006] Oubaku is a crude drug containing berberine as a main component together with spinach and ogon, but its usage in Chinese medicine is often different from spinach and ogon. There are many uses of oak for estimating bactericidal effects such as digestive effects and eye diseases. Also, the efficacy of oubaku is characterized by its use as an external preparation, and berberine is reported as a topical bactericide to have a wound healing promoting action that cannot be explained by mere bactericidal action.

【0007】クララはmatrineを主アルカロイド
とするもので、湿疹、水虫などの皮膚疾患、口内炎等に
用いられる
[0007] Clara is mainly made of matrine and is used for skin diseases such as eczema and athlete's foot, stomatitis and the like.

【0008】[0008]

【発明が解決しようとする問題点】 しかしこれらは従
来漢方薬として使用され、いわゆる煎じ薬として、又、
軟膏剤として使用されているが、その一般的薬理につい
ては殆ど実験段階であり、これらを組み合わせてその相
乗効果をもたらす使用方法は従来全く行われていなかっ
た。
[Problems to be solved by the invention] However, these are conventionally used as Chinese herbal medicines, so-called decoction,
Although it is used as an ointment, its general pharmacology is almost at the experimental stage, and there has been no method of combining these to produce a synergistic effect.

【0009】[0009]

【問題点を解決するための手段】 そこで本発明に於い
てはオウバク、オウゴンは共にベルベリンを主成分とす
る生薬であるが、夫々はベルベリンで代表される薬効と
明らかに相違するものがあり、又漢方における用法も様
々で異なることが多い点に着目し夫々の成分を有効に生
かし、更に皮膚障害治癒作用があり、抗アレルギー作用
を有するトリテルペノイト配糖体を6〜14%含有し、
その代表成分glycyrrhizinやglalri
cacid,gabrolide等数多くのサポゲニ
ン、多数のフラボノイド、フラボン類を利用できる甘草
を配し、接触性皮膚炎に有効なアレルギー性皮膚炎用ク
リームに仕立てんとするもので、グリチルリチン酸を主
体とする甘草抽出体を0.05〜0.5%を含有させる
ことを特徴とするアレルギー性皮膚炎用クリームと、基
材のスクワラン、ワセリン、流動パラフィンを加熱して
混和溶解し、これに防腐剤を含む熱精製水を加えて乳化
し、これにグリチルリチン酸を主体とする甘草抽出体及
びオウゴン抽出液、オウバク抽出液、クララ抽出液を加
えた後、撹拌しながら冷却させることを特徴とするアレ
ルギー性皮膚炎用クリームの製造方法を提案せんとする
ものである。
[Means for Solving the Problems] Accordingly, in the present invention, both Oubak and Ougon are crude drugs containing berberine as the main component, but each of them has a distinct difference from the drug efficacy represented by berberine. Focusing on the fact that the usage in Chinese medicine is often varied and different, each component is utilized effectively, and furthermore, it has a skin disorder healing effect, and contains 6 to 14% of a triterpenoid glycoside having an antiallergic effect,
Its representative components glycyrrhizin and glalri
A licorice that can utilize a large number of sapogenins, such as cadid and gabbrolide, a large number of flavonoids, and flavones, and is tailored to a cream for allergic dermatitis that is effective for contact dermatitis, and is mainly composed of glycyrrhizic acid. A cream for allergic dermatitis characterized by containing 0.05 to 0.5% of the extract, and squalane, petrolatum and liquid paraffin as base materials are mixed and dissolved by heating, and a preservative is contained therein. Allergic skin characterized by adding heat-purified water to emulsify, adding a licorice extract mainly composed of glycyrrhizic acid, a pentagon extract, a oak extract and a Clara extract, and then cooling while stirring. It is intended to propose a method for producing a flame cream.

【0010】[0010]

【実施例】 以下、実施例により本発明を詳細に説明す
る。先ず、乳化剤としてモノステアリン酸グリセリン、
ポリオキシエチレン硬化ヒマシ、防腐剤としてパラオ
キシ安息香酸ブチルを加熱して混和溶解する。これに防
腐剤パラオキシ安息香酸メチルを溶解した熱精製水を加
えて乳化する。これに甘草エキスであるが、glycy
rrhizinやそのゲニンのglycyrrheti
c acidは副腎皮質の水電解質や糖質ホルモン様作
用、エストロゲン作用、鎮咳作用、抗炎症作用、抗アレ
ルギー作用など数多くの薬理効果があるが、これを主剤
として0.05〜0.5%まで含有させる。甘草には多
数のグリチルリチン酸があるが、グリチルリチン酸モノ
アカモニウム及びカリウムは熱水には溶けるが、放冷す
るとゲル状になり、冷水には溶けにくい。P−グリチル
リチン酸はピリジンに溶けやすく、水には殆ど溶けない
等水に溶けないものが多い中でグリチルリチン酸ジカリ
ウムは常温で水に85%溶解するので使用し易い。又、
酸化防止剤としてトコフェロール就中、酢酸−dl−α
−トコフェロールを適量加える。
The present invention will be described below in detail with reference to examples. First, glyceryl monostearate as an emulsifier,
Polyoxyethylene hydrogenated castor oil and butyl parahydroxybenzoate as a preservative are mixed and dissolved by heating. To this is added hot purified water in which a preservative, methyl parahydroxybenzoate, is dissolved to emulsify. This is licorice extract, but glycy
glycyrrheti of rrhizin and its genin
C acid has a number of pharmacological effects such as a water electrolyte in the adrenal cortex, a carbohydrate-like action, an estrogen action, an antitussive action, an anti-inflammatory action, an anti-allergic action, and up to 0.05 to 0.5% based on this. To be included. Licorice contains a large number of glycyrrhizic acids. Monoacmonium and potassium glycyrrhizinates dissolve in hot water, but form a gel when left to cool, and are difficult to dissolve in cold water. P-glycyrrhizic acid is easily soluble in pyridine, and in many cases insoluble in water, such as insoluble in water, and dipotassium glycyrrhizinate is 85% soluble in water at room temperature, so that it is easy to use. or,
Tocopherol as an antioxidant, especially acetic acid-dl-α
-Add an appropriate amount of tocopherol.

【0011】次にオウゴンは主成分のフラボノイドはb
aicalin4.3%、baicalein、wog
onin0.5%、wogonin glucuron
ide、orxylinA、この他ステロイド、糖類が
存在するオウゴンの抗アレルギー作用の有効成分はba
icalinであり、そのgluconのbaical
einはモル比でbaicalinと同程度のmedi
ator遊離抑制作用を示したので活性構造はbaic
lein部分にある。baicleinはanaphy
lexis型反応を抑制するのみならず、reagin
によって惹起されるアトピー型の反応をも抑制する。
Next, the pentagon is a flavonoid whose main component is b.
aicalin 4.3%, baicalein, wog
onin0.5%, woginin glucuron
ide, orxylin A, and other active ingredients for the antiallergic action of gon, which contains steroids and saccharides, are ba
icalin and its glucon baical
ein is a medi equivalent to baicalin in molar ratio
active structure since showed ator release suppression effect baic
in the lein part. bailein is anaphy
Not only suppresses lexis-type reaction,
It also suppresses the atopic type reaction caused by the

【0012】又、アトピー型抑制剤であるrisodi
um cromoglycate(DSCG)はbai
caleinと共通のchromono骨格を持つが、
DSCGはreaginによる反応しか押さえられない
のに対しbaicaleinはnon−reaginに
よる反応をも押さえることが出来る。以上のことからb
aicaleinがアレルギー反応の発現の機序のうち
従来の薬物では及ばない作用点に作用することが解か
る。又、オウゴンは赤痢菌、チフス菌、緑膿菌、ブドウ
球菌、溶血性レンサ球菌等に対し、抗菌作用があるとす
る主張がある。
Also, risodi, an atopic inhibitor,
um chromoglycate (DSCG) is bai
It has a chromono skeleton common to Calein,
DSCCG can suppress only the reaction due to reagent, whereas baicalein can also suppress the reaction due to non-reagin. From the above, b
It can be seen that aicalein acts on the site of action of the allergic reaction that is lower than that of conventional drugs. In addition, it has been claimed that Orgon has antibacterial activity against Shigella, Salmonella typhi, Pseudomonas aeruginosa, staphylococci, hemolytic streptococci and the like.

【0013】これらオウゴンは日局オウゴンのエタノー
ルによる抽出物を1.3−ブチレングリコールに溶解し
たものでbaicalin0.15〜0.25w/v%
含むが、これを全体の1〜10%加える。
These gougins are obtained by dissolving an extract of the Japanese gougon with ethanol in 1.3-butylene glycol, and containing 0.15 to 0.25% w / v baicalin.
But add 1-10% of the total.

【0014】オウバクは殺菌作用を有すること前述した
が、ブドウ球菌に対し5%で発育阻止作用を認められ、
肺炎菌には最も強い抗菌力を示し、ベルベリン0.62
5%、オウバク末は0.015%の濃度まで阻止作用を
示した。
As described above, oak has a bactericidal action, but a growth inhibitory action against staphylococci was observed at 5%.
B. pneumoniae has the strongest antibacterial activity, berberine 0.62
5% and oak powder showed an inhibitory effect up to a concentration of 0.015%.

【0015】又オウバクの薬効には単なる殺菌作用の強
さでは説明できない創面治癒作用があるが、例えばウサ
ギは背部皮膚に作成した筋肉に達した2cmの新鮮創
傷の治癒はアクリノールに比べてベルベリン溶液処理群
が明らかに早かった。試験管での殺菌効力は明らかに合
成殺菌剤に比し弱いので、収斂性の抗炎症作用が治癒の
促進に関与しているものと思われる。又オウバクのアル
カロイド以外の成分としてリノール酸、パルミチン酸と
フィトステリンのエステルが同定されている。
The efficacy of oak has a wound healing effect that cannot be explained by the strength of mere bactericidal action. For example, in rabbits, the healing of a fresh wound of 2 cm 2 reaching the muscle formed on the back skin is healed as compared to berberine compared to acrinol. The solution treatment group was clearly faster. Since the bactericidal efficacy in test tubes is clearly weaker than synthetic bactericides, it is likely that astringent anti-inflammatory effects are involved in promoting healing. In addition, esters of linoleic acid, palmitic acid and phytosterin have been identified as components other than oak alkaloids.

【0016】古来オウバク末は火傷、湯ただれに用いら
れ、近年では受精卵を用いた抗炎症作用のスクリーニン
グ研究に於いて強い抗炎症作用検出されている。即ち、
受精鶏卵の胚に検体を浸漬した濾紙のディスクを作用さ
せ肉芽形成を阻害する作用を指標として活性を調べたと
ころ、オウバクの50%メタノール抽出粗エキスは50
0μg/diseの用量で53%の肉芽阻止作用を示し
た。塩酸ベルベリンは50μg/diseの用量で6
8.8%の抑制を示した。オウバクの炎症に関与する成
分は明確でない。日局オウバクの1.3ブチレングリコ
ール抽出液で、ベルベリンを塩化ベルべリンとして0.
15〜0.25w/v%含むものを使用し、全体の1〜
10%を含有させる。
[0016] Since ancient times, powdered oak powder has been used for burns and soaking, and in recent years, strong anti-inflammatory action has been detected in screening studies of anti-inflammatory action using fertilized eggs. That is,
When the activity of the filter paper disc in which the specimen was immersed in the embryo of the fertilized chicken egg was allowed to act to inhibit the granulation formation as an index, the crude extract of 50% methanol extracted from oak was 50%.
At a dose of 0 μg / dise, the granulation inhibitory effect was 53%. Berberine hydrochloride is 6 at a dose of 50 μg / dise.
8.8% inhibition was shown. The components involved in oak inflammation are unclear. Berberine was converted to berberine chloride in a 1.3-butylene glycol extract of Oubaku Japan Pharmacopoeia.
Use those containing 15 to 0.25 w / v%,
Contains 10%.

【0017】クララはマメ化のsophora fla
vecens Aitonの根をそのまま50v/v%
エタノール溶液で抽出したものに1.3−ブチレングリ
コールと精製水の混液を加えたもので、アルカロイドの
主成分である(+)−matrine、副成分たる
(+)−oxynatrine等を含有し、又フラボノ
類としてXanthoumol、isoranthoh
amol等を含有する。これらは皮膚疾患、皮膚感染
症、あせも、ただれ、陰部掻痒症等に用いられる。又、
蛇床子と合わせると止痒効果が強まる。該クララ液を全
体の1〜10%を含有させる。
Clara is a sophora fla
vecens Aiton root as it is 50v / v%
A mixture of 1.3-butylene glycol and purified water added to an ethanol-extracted solution, containing (+)-matrine, the main component of alkaloids, and (+)-oxynatrine, a minor component, and Xanthoumol, isolanthoh as flavonos
amol etc. They are used for skin diseases, skin infections, hot flashes, sores, genital pruritus and the like. or,
When combined with snakebed, itching effect is enhanced. The Clara liquor contains 1 to 10% of the whole.

【0018】前述の乳化剤に甘草エキス就中グリリチル
酸ジカリウム、酸化防止剤の酢酸−dl−α−トコフェ
ロール及びオウゴン抽出液、オウバク抽出液、クララ抽
出液を各1〜10%加えた後、撹拌しながら冷却し、製
品を得る。
To the above-mentioned emulsifier, 1-10% each of a licorice extract, of which dipotassium glycylate, an antioxidant dl-α-tocopherol acetic acid, a pentagon extract, an oak extract and a Clara extract, are added, followed by stirring. While cooling, get the product.

【0019】〔実用例1〕 グリチルリチン酸ジカリウム 0.05% 酢酸−dl−α−トコフェロール 0.05% スクワラン 10.0% ワセリン 25.0% 流動パラフィン 15.0% ベヘニルアルコール 2.0% テトラォレィン酸ポリオキシ エチレンソルビット(60B.O) 2.0% モノステアリン酸グリセリン 7.0% ポリオキシエチレン硬化ヒマシ油 5.0% パラオキシ安息香酸ブチル 適量 オウゴン抽出液 1.0% 精製水 残[Practical Example 1] dipotassium glycyrrhizinate 0.05% acetic acid-dl-α-tocopherol 0.05% squalane 10.0% petrolatum 25.0% liquid paraffin 15.0% behenyl alcohol 2.0% polyoxytetraoleate Ethylene sorbite (60BO) 2.0% Glycerin monostearate 7.0% Polyoxyethylene hydrogenated castor oil 5.0% Appropriate amount of butyl parahydroxybenzoate Ogon extract 1.0% Purified water residue

【0020】〔実用例2〕 グリチルリチン酸ジカリウム 0.3% 酢酸−d1−α−トコフェロール 1.0% スクワラン 15.0% ワセリン 15.0% 流動パラフィン 15.0% ベヘニルアルコール 5.0% テトラオレイン酸ポリオキシ エチレンソルビット(60B.O) 2.0% モノステアリン酸グリセリン 7.0% ポリオキシエチレン硬化ヒマシ油 5.0% パラオキシ安息香酸ブチル 適量 オウゴン抽出液 1.0% オウバク抽出液 7.0% 精製水 残 上記のクリームは抗アレルギー作用を有しながら、殺菌
作用が高まることが判明した。
Practical Example 2 Dipotassium glycyrrhizinate 0.3% -d1-α-tocopherol acetate 1.0% Squalane 15.0% Vaseline 15.0% Liquid paraffin 15.0% Behenyl alcohol 5.0% Tetraoleic acid Polyoxyethylene sorbite (60BO) 2.0% Glycerin monostearate 7.0% Polyoxyethylene hydrogenated castor oil 5.0% Butyl paraoxybenzoate qs Oung extract 1.0% Oubak extract 7.0% Purification Water remaining It was found that the above cream has an antiallergic effect, but also has a higher bactericidal effect.

【0021】〔実用例3〕 グリチルリチン酸ジカリウム 0.08% 酢酸−d1−α−トコフェロール 0.05% スクワラン 10.0% ワセリン 20.0% 流動パラフィン 15.0% ベヘニルアルコール 2.0% テトラオレイン酸ポリオキシ エチレンソルビット(60B.O) 2.0% モノステアリン酸グリセリン 6.0% ポリオキシエチレン硬化ヒマシ油 6.0% パラオキシ安息香酸ブチル 適量 オウゴン抽出液 1.0% オウバク抽出液 1.0% クララ抽出液 10.0% パラオキシ安息香酸メチル 適量 精製水 残 上記のクリームは止痒効果が優れていることが判明し
た。
[Practical Example 3] Dipotassium glycyrrhizinate 0.08% -d1-α-tocopherol acetate 0.05% Squalane 10.0% Vaseline 20.0% Liquid paraffin 15.0% Behenyl alcohol 2.0% Tetraoleic acid Polyoxyethylene sorbit (60BO) 2.0% Glycerin monostearate 6.0% Polyoxyethylene hydrogenated castor oil 6.0% Butyl paraoxybenzoate Appropriate amount Ougon extract 1.0% Oubak extract 1.0% Clara Extract 10.0% Methyl parahydroxybenzoate Appropriate amount Purified water residue The above cream was found to have an excellent antipruritic effect.

【0022】各実用例について洗髪シャンプー、リンス
等に毎日接触しており、且つ、皮膚に炎症のある美容師
多数人に使用して頂いた処、その炎症にもよるが、早い
人で数日、遅い人でも数週間以内にかゆみがとれ、炎症
が治った、又は軽くなった。各実用例間の差については
症例が少なく、判明するのに時間が必要である。
For each practical example, many hairdressers who are in daily contact with hair washing shampoo, rinse, etc. and have inflammation on the skin have used it. Even within a few weeks, itching disappeared, and the inflammation healed or diminished. There are few cases of differences between the practical examples, and it takes time to find out.

【0023】下記に実用例1の使用例の効果を示す。実
用例1による手皮膚炎に対する有効率
The effects of the usage example of practical example 1 will be described below. Effective Rate for Hand Dermatitis by Practical Example 1

【0024】下記に実用例2の使用例の効果を示す。実
用例2による手皮膚炎に対する有効率
The effects of the practical example 2 will be described below. Effective Rate for Hand Dermatitis by Practical Example 2

【0025】又、各実用例ともアトピー性皮膚炎に対し
有効性が高いことが判明した。アレゲルンは単一でなく
複合的なものであるため、複合的な本品によって対症効
果がでる。又、これら実用例に対し、マレイン酸クロフ
ェニラミンを抗ヒスタミンとして配合したが、かゆみの
剌激が中和されて有効であることが判かった。
Further, it was found that each practical example is highly effective against atopic dermatitis. Allegern is not a single substance but a complex substance, so the combined use of this product provides a symptomatic effect. In addition, clophenylamine maleate was added as an antihistamine to these practical examples, but it was found that the stimulation of itching was neutralized and effective.

【0026】実施例3によるアトピー性皮膚炎の汗疹性
苔癬化型に対する有効率を示す。下段は坑ヒスタミン配
合の使用例を示す。
2 shows the effective rate of atopic dermatitis according to Example 3 to the lichenosis type of eczema. The lower part shows a usage example of the antihistamine compound.

【0027】[0027]

【発明の効果】 上記の如き本発明によれば、グリチル
リチン酸を主体とする甘草抽出体を0.05〜0.5
%、オウゴン抽出液を1〜10%、オウバク抽出液を1
〜10%、クララ抽出液を1〜10%を含有させたアレ
ルギー性皮膚炎用クリームを、基材のスクワラン、ワセ
リン、流動パラフィンを加熱して混和溶解し、これに防
腐剤を含む熱精製水を加えて乳化し、これにグリチルリ
チン酸を主体とする甘草抽出体及びオウゴン抽出液、オ
ウバク抽出液、クララ抽出液を加えた後、撹拌しながら
冷却させて製造するようにしたので、甘草エキスの有す
る抗炎症作用、オウゴン抽出液のフラボノイドとしての
抗炎症作用、抗アレルギー作用、アトピー型反応の抑制
作用、オウバク抽出液の有するベルベリン、アルカロイ
ド等による収斂状の抗炎症作用を基とする創面治癒促進
作用、抗炎症作用、クララ抽出液の有する主アルカロイ
トのマトリンの潰瘍発生予防能力、皮膚感染症の対応力
等の夫々の能力が組合わさり、夫々の効果と共に相乗効
果を挙げ、極めて優れたアレルギー性皮膚炎用クリーム
を提供することが出来る。
According to the present invention as described above, a licorice extract mainly containing glycyrrhizic acid is used in an amount of 0.05 to 0.5.
%, 1-10% of pentagon extract, 1 part of pentagon extract
Heat purified squalane, petrolatum, and liquid paraffin are mixed and dissolved in a cream for allergic dermatitis containing 10% to 10% of Clara extract and heat purified water containing a preservative. And emulsify, add glycyrrhiz
The licorice extract mainly composed of carboxylic acid and the extract of pentagon, the extract of oak, the extract of oak, and the extract of Clara were added and cooled with stirring. Anti-inflammatory action, anti-allergic action, atopy-type reaction suppression action as a flavonoid, promotion of wound healing based on astringent anti-inflammatory action by berberine, alkaloid, etc. in oak extract, anti-inflammatory action, Clara extraction To provide an extremely excellent cream for allergic dermatitis by combining the respective abilities of the main alkaloid having the liquid, such as matrine ulcer occurrence prevention ability and the ability to respond to skin infections, with synergistic effects together with the respective effects. Can be done.

Claims (3)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 グリチルリチン酸を主体とする甘草抽出
体を0.05〜1.0%、オウゴン抽出液を0.1〜5
%を含有させることを特徴とするアレルギー性皮膚炎用
クリーム。
1. A licorice extract mainly composed of glycyrrhizic acid in an amount of 0.05 to 1.0%, and an extract of a pentagon in an amount of 0.1 to 5%.
% For allergic dermatitis.
【請求項2】 オウバク抽出液を0.1〜10%を含有
させることを特徴とする請求項1に記載のアレルギー性
皮膚炎用クリーム。
2. The cream for allergic dermatitis according to claim 1, wherein the extract contains oat extract at 0.1 to 10%.
【請求項3】 基材のスクワラン、ワセリン、流動パラ
フィンを加熱して混和溶解し、これに防腐剤を含む熱精
製水を加えて乳化し、これにグリチルリチン酸を主体と
する甘草抽出体及びオウゴン抽出液を加えた後、撹拌し
ながら冷却させることを特徴とするアレルギー性皮膚炎
用クリームの製造方法。
3. Squalane, Vaseline, Liquid para
Heat and mix and dissolve the fins.
Add water and emulsify to make glycyrrhizic acid the main component.
After adding the licorice extract and pentagon extract,
Allergic dermatitis characterized by cooling while cooling
Method of making cream for use.
JP3151176A 1991-05-27 1991-05-27 Cream for allergic dermatitis and method for producing the same Expired - Fee Related JP2609562B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3151176A JP2609562B2 (en) 1991-05-27 1991-05-27 Cream for allergic dermatitis and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3151176A JP2609562B2 (en) 1991-05-27 1991-05-27 Cream for allergic dermatitis and method for producing the same

Publications (2)

Publication Number Publication Date
JPH04346917A JPH04346917A (en) 1992-12-02
JP2609562B2 true JP2609562B2 (en) 1997-05-14

Family

ID=15512968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3151176A Expired - Fee Related JP2609562B2 (en) 1991-05-27 1991-05-27 Cream for allergic dermatitis and method for producing the same

Country Status (1)

Country Link
JP (1) JP2609562B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150132417A1 (en) * 2008-12-23 2015-05-14 The Dial Corporation Combinations of herb extracts having synergistic antioxidant effect, and methods relating thereto
KR20190060291A (en) 2017-11-24 2019-06-03 (주)아모레퍼시픽 Composition for preventing or improving atopic dermatitis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2609564B2 (en) * 1991-05-31 1997-05-14 政夫 斎藤 Cream for allergic dermatitis and method for producing the same
JP2609563B2 (en) * 1991-05-31 1997-05-14 政夫 斎藤 Cream for allergic dermatitis and method for producing the same
EP1374861A1 (en) * 1995-04-21 2004-01-02 Sekisui Kagaku Kogyo Kabushiki Kaisha External preparations for treating dermatoses
JPH09169637A (en) * 1995-10-18 1997-06-30 Sekisui Chem Co Ltd External preparation for treating dermatosis
JP2001064192A (en) * 1999-08-25 2001-03-13 Sunstar Inc Migration inhibitor for langerhans cell and antigen presentation inhibitor
KR100862968B1 (en) * 2007-02-21 2008-10-13 바이오스펙트럼 주식회사 Agents for Improving Wrinkles on Skin Comprising Matrine or Its Oxidized Derivatives
JP2009114146A (en) * 2007-11-08 2009-05-28 Maruzen Pharmaceut Co Ltd Transglutaminase-1 production promoter and involucrin production promoter
CN112843113B (en) * 2021-03-23 2022-02-01 南京医科大学 A preparation for treating contact dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53136509A (en) * 1977-05-04 1978-11-29 Akira Hamaguchi Production of dermatophytosis treating agent
JPS62292725A (en) * 1986-06-12 1987-12-19 Nitto Electric Ind Co Ltd Remedy for insect bite
JPH01305034A (en) * 1988-06-01 1989-12-08 Teika Corp Production of 'ougon' extract and cosmetic containing the same
JPH0236113A (en) * 1988-07-26 1990-02-06 Ichimaru Pharcos Co Ltd External use of scutellariae radix powder

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150132417A1 (en) * 2008-12-23 2015-05-14 The Dial Corporation Combinations of herb extracts having synergistic antioxidant effect, and methods relating thereto
US9724375B2 (en) * 2008-12-23 2017-08-08 Henkel IP & Holding GmbH Combinations of herb extracts having synergistic antioxidant effect, and methods relating thereto
KR20190060291A (en) 2017-11-24 2019-06-03 (주)아모레퍼시픽 Composition for preventing or improving atopic dermatitis

Also Published As

Publication number Publication date
JPH04346917A (en) 1992-12-02

Similar Documents

Publication Publication Date Title
TW550079B (en) A novel pharmaceutical composition for the control and treatment of anorectal and colonic diseases and a process for the manufacture thereof
JP2609564B2 (en) Cream for allergic dermatitis and method for producing the same
US10967030B2 (en) Traditional Chinese medicine composition for treating psoriasis and method for preparing the same
JP2609562B2 (en) Cream for allergic dermatitis and method for producing the same
JPH02117619A (en) Cosmetic composition and paramedical composition
RU2438692C2 (en) Vegetable extract and its therapeutic application
US20170000836A1 (en) Prognostic and Diagnostic Methods and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer
WO2019132625A1 (en) Composition for preventing, improving or treating atopic dermatitis containing mixed herbal extract as active ingredient
WO2003099200A2 (en) Composition and method for the treatment of diaper rash using natural products
JP2609563B2 (en) Cream for allergic dermatitis and method for producing the same
US10780141B2 (en) Herbal combinations for treating eczema
US20170000837A1 (en) Prognostic and Diagnostic Kits and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer
EP1819352A1 (en) Pharmaceutical compositions from carapa guianensis
DE602004005183T2 (en) PHARMACEUTICAL COMPOSITIONS USING EXTRACT FROM EUPHORBIA PROSTRATA
KR20120044396A (en) Composition for improving atopic dermatitis comprising extract of quercus variabilis which is extracted from wood chip of quercus variabilis obtained by steam explosion treatment
JPH05502457A (en) Kava kava extracts, their manufacturing process and uses
US20170049688A1 (en) Herbal Combinations For Treating Psoriasis
Aina et al. In vitro investigations into the antioxidant and anti-Inflammatory potentials of the fractions and ethanolic extract of Cyclosorus afer (christ.) Ching, stalks
CN111374970B (en) Composition with anti-colitis activity and application thereof
JP4241958B2 (en) Androgen receptor binding inhibitor
JPH0429934A (en) Externally applicable composition containing extracted essence of ginkgo leaf
JP5061143B2 (en) Topical skin preparation
JP2001131079A (en) Skin preparation for external use
CN111358851A (en) Gel for treating pet skin diseases and preparation method thereof
KR101084727B1 (en) Composition for inhibiting release of histamine comprising extract or a saponin of Codonopis lanceolata

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 19961022

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090213

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100213

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110213

Year of fee payment: 14

LAPS Cancellation because of no payment of annual fees